A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- Registration Number
- NCT05047250
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with stage IV non-squamous or squamous NSCLC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 60
- ECOG performance status of 0 or 1.
- Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC.
- No prior treatment for Stage IV non-squamous or squamous NSCLC.
- Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 6 months from enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy cycle.
- Tumor TC3 or IC3, as determined by SP142 performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening.
- Measurable disease, as defined by RECIST v1.1.
- Adequate hematologic and end-organ function.
- Life expectancy ≥3 months.
- For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating.
- Known sensitizing mutation in the EGFR gene or ALK fusion oncogene.
- Symptomatic, untreated, or actively progressing CNS metastases.
- Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥2 weeks prior to enrollment.
- Current leptomeningeal disease.
- Uncontrolled tumor-related pain.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
- Uncontrolled or symptomatic hypercalcemia.
- Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.
- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab.
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
- Known allergy or hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation.
- Active or history of autoimmune disease or immune deficiency.
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
- Positive human immunodeficiency virus (HIV) test result at screening.
- Patients with active hepatitis B or active hepatitis C at screening.
- Active tuberculosis.
- Severe infections within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
- Significant cardiovascular disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Atezolizumab Atezolizumab Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
- Primary Outcome Measures
Name Time Method Overall survival (OS) Atezolizumab initiation to death from any cause (up to approximately 28 months) Overall survival (OS) is defined as the time from atezolizumab initiation to death from any cause.
- Secondary Outcome Measures
Name Time Method Progression-free survival (PFS) Atezolizumab initiation to the first occurrence of disease progression or death from any cause (whichever occurs first), (up to approximately 28 months) Progression-free survival (PFS) is defined as the time from atezolizumab initiation to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by investigators according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1).
OS Rate at 1-Year Atezolizumab initiation to 1-year OS rate at 1-year is defined as the probability of participants who have not experienced death from any cause at 1-year after atezolizumab initiation.
OS Rate at 2-Year Atezolizumab initiation to 2-year OS rate at 2-year is defined as the probability of participants who have not experienced death from any cause at 2-year after atezolizumab initiation.
Objective Response Rate (ORR) Randomization up to approximately 34 months Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR), as determined by investigators according to RECIST v1.1.
Duration of Response (DOR) Randomization up to approximately 34 months Duration of response (DOR) is defined as the time from the first occurrence of an objective response to disease progression or death from any cause (whichever occurs first), as determined by investigators according to RECIST v1.1.
Percentage of Participants With Adverse Events Randomization up to approximately 34 months Percentage of participants with adverse events.
Trial Locations
- Locations (23)
Xuanwu Hospital, Capital Medical University
🇨🇳Beijing City, China
Beijing Tiantan Hospital,Capital Medical University
🇨🇳Beijing, China
Beijing Chest Hospital
🇨🇳Beijing, China
The Third Xiangya Hospital Of Central South University
🇨🇳Changsha, China
Changzhou First People's Hospital
🇨🇳Changzhou, China
Daping Hospital of Third Military Medical University
🇨🇳Chongqing, China
Fujian Cancer Hospital
🇨🇳Fuzhou, China
Sir Run Run Shaw Hospital Zhejiang University
🇨🇳Hangzhou City, China
The Second Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, China
Anhui Province Cancer Hospital
🇨🇳Hefei City, China
Scroll for more (13 remaining)Xuanwu Hospital, Capital Medical University🇨🇳Beijing City, China